Pharming Group Investor Relations Material

Pharming Group N.V. is a global biopharmaceutical company based in Leiden, the Netherlands. The company specializes in the development and commercialization of protein replacement therapies and precision medicines, particularly for rare diseases. Pharming's key product is RUCONEST, a plasma-free recombinant human C1 esterase inhibitor used for treating acute hereditary angioedema (HAE). The company also has several other products in various stages of development, including treatments for Pompe and Fabry diseases and other rare disorders. The company is headquartered in Leiden, the Netherlands, and its shares are listed on both the Amsterdam Euronext and Nasdaq.